Adapted whole-body surveillance for von Hippel–Lindau-associated tumors in 3p deletion syndrome with VHL deletion: A case report

Kazumi Morisawa; Takeshi Sato; Motoko Shimoyamada; Ryuichi Mizuno; Hirofumi Ohashi; Hiromi Watanabe-Hisazumi; Kaoru Takeshima; Atsuhiro Kojima; Seiji Sato; Tomonobu Hasegawa; Takao Takahashi

doi:10.1002/pbc.29732

Adapted whole-body surveillance for von Hippel–Lindau-associated tumors in 3p deletion syndrome with VHL deletion: A case report

Kazumi Morisawa, Takeshi Sato, Motoko Shimoyamada, Ryuichi Mizuno, Hirofumi Ohashi, Hiromi Watanabe-Hisazumi, Kaoru Takeshima, Atsuhiro Kojima, Seiji Sato, Tomonobu Hasegawa, Takao Takahashi

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	e29732
Journal	Pediatric Blood and Cancer
Volume	69
Issue number	11
DOIs	https://doi.org/10.1002/pbc.29732
Publication status	Published - 2022 Nov

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.29732

Cite this

Morisawa, K., Sato, T., Shimoyamada, M., Mizuno, R., Ohashi, H., Watanabe-Hisazumi, H., Takeshima, K., Kojima, A., Sato, S., Hasegawa, T., & Takahashi, T. (2022). Adapted whole-body surveillance for von Hippel–Lindau-associated tumors in 3p deletion syndrome with VHL deletion: A case report. Pediatric Blood and Cancer, 69(11), [e29732]. https://doi.org/10.1002/pbc.29732

@article{6153e1c81942481b96362f0f52d8f38b,

title = "Adapted whole-body surveillance for von Hippel–Lindau-associated tumors in 3p deletion syndrome with VHL deletion: A case report",

author = "Kazumi Morisawa and Takeshi Sato and Motoko Shimoyamada and Ryuichi Mizuno and Hirofumi Ohashi and Hiromi Watanabe-Hisazumi and Kaoru Takeshima and Atsuhiro Kojima and Seiji Sato and Tomonobu Hasegawa and Takao Takahashi",

note = "Funding Information: Tomonobu Hasegawa has the following financial relationships to disclose: Research funding from Novo Nordisk Pharma Ltd. and JCR Pharmaceuticals Co., Ltd. The other authors have no conflict of interest. Funding Information: informationNovo Nordisk Pharma Ltd.; JCR Pharmaceuticals Co., Ltd.We thank the patient's family for their participation in this study.",

year = "2022",

month = nov,

doi = "10.1002/pbc.29732",

language = "English",

volume = "69",

journal = "Medical and Pediatric Oncology",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Adapted whole-body surveillance for von Hippel–Lindau-associated tumors in 3p deletion syndrome with VHL deletion

T2 - A case report

AU - Morisawa, Kazumi

AU - Sato, Takeshi

AU - Shimoyamada, Motoko

AU - Mizuno, Ryuichi

AU - Ohashi, Hirofumi

AU - Watanabe-Hisazumi, Hiromi

AU - Takeshima, Kaoru

AU - Kojima, Atsuhiro

AU - Sato, Seiji

AU - Hasegawa, Tomonobu

AU - Takahashi, Takao

N1 - Funding Information: Tomonobu Hasegawa has the following financial relationships to disclose: Research funding from Novo Nordisk Pharma Ltd. and JCR Pharmaceuticals Co., Ltd. The other authors have no conflict of interest. Funding Information: informationNovo Nordisk Pharma Ltd.; JCR Pharmaceuticals Co., Ltd.We thank the patient's family for their participation in this study.

PY - 2022/11

Y1 - 2022/11

UR - http://www.scopus.com/inward/record.url?scp=85128351478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128351478&partnerID=8YFLogxK

U2 - 10.1002/pbc.29732

DO - 10.1002/pbc.29732

M3 - Letter

C2 - 35441425

AN - SCOPUS:85128351478

SN - 1545-5009

VL - 69

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

IS - 11

M1 - e29732

ER -

Adapted whole-body surveillance for von Hippel–Lindau-associated tumors in 3p deletion syndrome with VHL deletion: A case report

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this